EGFR and non-small cell lung carcinoma: The NCT03513666 trial was a phase 2 study that evaluated toripalimab (anti-PD-1) + platinum doublet chemotherapy in patients with EGFRm advanced NSCLC who developed PD on first- and second-generation EGFR TKIs without T790M mutation (51).